|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM298438860 |
| 003 |
DE-627 |
| 005 |
20231225094146.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.06.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0994.xml
|
| 035 |
|
|
|a (DE-627)NLM298438860
|
| 035 |
|
|
|a (NLM)31229666
|
| 035 |
|
|
|a (PII)S1521-6616(18)30753-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Luah, Yen Hoon
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A novel simplified method of generating cytomegalovirus-specific cytokine-induced killer cells of high specificity and superior potency with GMP compliance
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.04.2020
|
| 500 |
|
|
|a Date Revised 20.04.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We describe a method of rendering polyclonal cytokine-induced killer cells (CIK) specific against cytomegalovirus (CMV), focusing on GMP compliance. Peripheral blood mononuclear cells (PBMNC) are stimulated with pooled CMV peptides pp65 and IE-1 for 16-24 h and the reactive T cell subset which up-regulate CD137 is further co-stimulated with anti-CD137, followed by expansion in G-Rex flasks under standard CIK culture condition. This method generates a large number CMV-specific CIK with superior potency compared to published method currently in clinical trials. The cytotoxicity as measured by chromium release assay correlates with the upregulation of CD107a upon peptide re-challenge as measured by flow cytometry. CMV-CIK at maturity consist of mainly late effector memory CD8 T cells and have a skewed TCR repertoire with preferential expansion of a few families. Such CMV-CIK retain their function after freezing and thawing. CMV-CIK thus generated is ready for clinical trial against drug-resistant CMV disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Allogeneic hematopoietic stem cell transplant
|
| 650 |
|
4 |
|a CD137 co-stimulation
|
| 650 |
|
4 |
|a Cell therapy
|
| 650 |
|
4 |
|a Cytokine-induced killer cells
|
| 650 |
|
4 |
|a Cytomegalovirus
|
| 650 |
|
7 |
|a IE1 protein, cytomegalovirus
|2 NLM
|
| 650 |
|
7 |
|a Immediate-Early Proteins
|2 NLM
|
| 650 |
|
7 |
|a Viral Matrix Proteins
|2 NLM
|
| 650 |
|
7 |
|a cytomegalovirus matrix protein 65kDa
|2 NLM
|
| 700 |
1 |
|
|a Sundar Raj, Kirubavathy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koh, Mickey B C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Linn, Yeh Ching
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 205(2019) vom: 15. Aug., Seite 83-92
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:205
|g year:2019
|g day:15
|g month:08
|g pages:83-92
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.06.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 205
|j 2019
|b 15
|c 08
|h 83-92
|